Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Steroidal aromatase inhibitors

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Steroidal aromatase inhibitors. Displaying page 1 of 1.
    EudraCT Number: 2014-005126-35 Sponsor Protocol Number: GBG86-DESIREE Start Date*: 2015-06-03
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer
    Medical condition: Advance Breast cancer under endocrine treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    21.1 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002157-64 Sponsor Protocol Number: Start Date*: 2012-03-07
    Sponsor Name:Common Services Agency
    Full Title: ARomatase Inhibition plus minus SaracaTinib as Advanced breast CAncer Therapy: a randomised phase II study of aromatase inhibition plus/minus the src-inhibitor AZD0530 in post-menopausal women with...
    Medical condition: Advanced breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002334-23 Sponsor Protocol Number: 2017-03 Start Date*: 2017-09-29
    Sponsor Name:Dutch Breast Cancer Research Group (BOOG)
    Full Title: Selecting the Optimal position of CDK4/6 Inhibitors in HR+ Advanced breast cancer: the SONIA trial
    Medical condition: hormone receptor positive advanced breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003170-27 Sponsor Protocol Number: GEICAM/2013-02 Start Date*: 2013-11-21
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: Phase III study of Palbociclib (PD-0332991) in combination with Exemestane versus chemotherapy (capecitabine) in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patient...
    Medical condition: Patients with hormonal receptor positive and HER2 negative MBC who are resistant to prior NSAI therapy.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) AT (Completed) HU (Completed) LV (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004517-84 Sponsor Protocol Number: ITFE-2026-C10 Start Date*: 2015-02-26
    Sponsor Name:ITF Research Pharma S.L.U
    Full Title: A PHASE II PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND MULTI-CENTRE CLINICAL TRIAL TO ASSESS THE SAFETY OF 0.005 % ESTRIOL VAGINAL GEL IN HORMONE RECEPTOR-POSITIVE POSTMENOPAUSAL ...
    Medical condition: In postmenopausal hormone receptor positive breast cancer, treatment with aromatase inhibitors is the most effective and well-studied therapy. Lack of adherence is common due to the side-effects; v...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000454-32 Sponsor Protocol Number: C/23/2011 Start Date*: 2012-01-17
    Sponsor Name:Imperial College London
    Full Title: A single arm phase IIa study (with combination safety run-in) to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole in ER positive breast cancer patients ...
    Medical condition: ER Positive Progressing Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000384-10 Sponsor Protocol Number: D6873C00047 Start Date*: 2005-03-15
    Sponsor Name:AstraZeneca AB
    Full Title: An Open-label, non-comparative, multi-centre study to assess the efficacy and safety of bicalutamide when used in combination with anastrozole for the treatment of gonadotropin-independent precocio...
    Medical condition: testotoxicosis (familial male-limited gonadotropin-independent precocious puberty)
    Disease: Version SOC Term Classification Code Term Level
    7.1 10063654 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-004035-38 Sponsor Protocol Number: GIM16-FEVEX Start Date*: 2015-06-17
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: Fulvestrant ed EVerolimus più EXemestane nel carcinoma mammario metastatico” “Fulvestrant followed by everolimus plus exemestane vs examestane and everolimus followed by fulvestrant in postmenopaus...
    Medical condition: Hormone receptor positive (HR+) and human epidermal growth factor receptor type 2 negative (HER2-) locally advanced (LABC) or metastatic breast cancer (MBC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006111-62 Sponsor Protocol Number: CRAD001JDE49 Start Date*: 2012-07-11
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination Wi...
    Medical condition: The trial aims to evaluate the efficacy, safety, quality of life and health resources in postmenopausal women with hormone receptor positive breast cancer progressing following prior therapy with N...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000710-11 Sponsor Protocol Number: SOLTI-1718 Start Date*: 2020-04-08
    Sponsor Name:SOLTI
    Full Title: Targeting EGFR/ERBB2 with Neratinib in Hormone Receptor (HR)-positive/HER2-negative HER2-enriched advanced/metastatic breast cancer (NEREA trial)
    Medical condition: Pre and post-menopausal women and men with locally advanced or metastatic HR+/HER2-negative endocrine resistant breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-008698-69 Sponsor Protocol Number: CRAD001Y2301 Start Date*: 2009-07-28
    Sponsor Name:NOVARTIS FARMA
    Full Title: A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metasta...
    Medical condition: estrogen receptor positive locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) CZ (Completed) NL (Completed) FR (Completed) BE (Completed) GB (Completed) DE (Completed) SE (Completed) ES (Completed) HU (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004860-22 Sponsor Protocol Number: IJB-BCTL:20120306 Start Date*: 2014-01-16
    Sponsor Name:Institute Jules Bordet
    Full Title: The [PEARL] Study : Pet imaging as a biomarker of Everolimus Added value in hormone Refractory postmenopausaL women
    Medical condition: Locally advanced or metastatic endocrine receptor positive and HER2 negative breast cancer refractory to non-steroidal aromatase inhibitors (NSAI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004234-15 Sponsor Protocol Number: CLEE011A2207 Start Date*: 2019-05-24
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- an...
    Medical condition: HR-positive, HER2-negative advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    23.0 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    21.1 100000004864 10072737 Advanced breast cancer LLT
    20.0 100000004864 10073289 Premenopausal breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) SE (Completed) CZ (Completed) FR (Completed) LT (Completed) AT (Completed) FI (Completed) DE (Completed) PT (Completed) HU (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002113-39 Sponsor Protocol Number: BAY88-8223/16298 Start Date*: 2014-10-29
    Sponsor Name:Bayer AG
    Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects ...
    Medical condition: HER2 negative hormone receptor positive metastatic breast cancer with bone metastases treated with standard of care hormonal treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) AT (Completed) NO (Completed) CZ (Completed) DK (Prematurely Ended) NL (Completed) SE (Completed) PL (Completed) FI (Completed) IE (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003131-11 Sponsor Protocol Number: 1280-0022 Start Date*: 2018-12-11
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: XeneraTM-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemest...
    Medical condition: HR+ / HER2- metastatic breast cancer and non-visceral disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) GR (Completed) PT (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000690-36 Sponsor Protocol Number: TED14856 Start Date*: 2018-12-17
    Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT
    Full Title: A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, then in Combination with Palbociclib in Postmenopausal...
    Medical condition: Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) PT (Prematurely Ended) ES (Prematurely Ended) CZ (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 05:09:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA